Stifel Lowers Price Targets on Multiple Stocks While Maintaining Buy Ratings

Stifel, a leading investment firm, has recently adjusted its price targets on several stocks while continuing to recommend a Buy rating on the companies. This move comes as Stifel reassesses its outlook on the market and individual stock performances.

One such example is the adjustment made to X4 Pharmaceuticals, with Stifel lowering the price target from $9.00 to $7.50. Despite the decrease, Stifel maintains its Buy rating on the pharmaceutical company, indicating confidence in its long-term potential.

Similarly, Stifel has revised its price target for Klaviyo Inc to $40.00 from $42.00, reflecting a conservative outlook for 2026. The Buy rating on Klaviyo Inc remains unchanged, suggesting Stifel’s belief in the company’s ability to weather market challenges.

HubSpot Inc also saw a reduction in price target from $600.00 to $550.00 by Stifel, while the Buy rating was upheld. This adjustment was made in response to growth concerns, but Stifel remains optimistic about the future prospects of the customer relationship management software provider.

Stifel’s adjustments extend beyond the technology sector, with changes made to the price targets of companies like Dutch Bros and CAVA. Despite lowering the price targets for these companies, Stifel maintains its Buy rating, indicating a positive stance on their performance in the market.

Overall, Stifel’s decision to lower price targets on various stocks while maintaining Buy ratings underscores the complexities of the current market environment. Investors may find value in considering Stifel’s assessments as they navigate their investment strategies in the coming months.